IDEXX LABORATORIES INC /DE
IDXXIn Vitro & In Vivo Diagnostic Substances · SIC 2835 · CIK 0000874716
Revenue FY2025
$4.30B
Net Income
$1.06B
EPS (Basic)
$13.17
Net Margin
24.6%
ROE
66.0%
Total Equity
$1.61B
Shares Out
79M
IDEXX LABORATORIES INC /DE — In Vitro & In Vivo Diagnostic Substances. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2008–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 15 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
Fundsmith
Terry Smith
$536.9M
1.4%
(30.4%)
Polen Capital Management
Polen
$280.3M
1.2%
(23.5%)
Jensen Investment Management
Jensen
$55.6M
0.9%
+2,861.0%
Platinum Investment Management
Platinum Investment Management
$1.5M
0.4%
(3.3%)
Weitz Investment Management
Wallace Weitz
$18.6M
0.2%
—
Holocene Advisors
Holocene Advisors
$92.4M
0.2%
+18.8%
Motley Fool Asset Management
Motley Fool Asset Management
$3.6M
0.1%
(11.7%)
Renaissance Technologies
Renaissance Technologies
$57.8M
0.1%
+126.3%
Capital Research Global Investors
Capital Research Global Investors
$415.5M
0.1%
+1.0%
Adage Capital Management
Adage Capital Management
$37.0M
0.1%
+2.9%
Bridgewater Associates
Bridgewater Associates
$17.7M
0.0%
+225.1%
Mairs & Power
Mairs & Power
$1.1M
0.0%
—
Alps Advisors
Alps Advisors
$0.9M
0.0%
+104.6%
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
$0.2M
0.0%
—
Oakmark Funds (Harris Associates)
Bill Nygren
$0.2M
0.0%
(5.6%)
Insider Transactions
Reading stored insider transactions…